In a stable 45‑year‑old man with known atrioventricular nodal reentrant tachycardia presenting with a regular narrow‑complex tachycardia at 150–170 bpm, is it appropriate to give an 18‑mg rapid IV bolus of adenosine as the first dose, and what should be the next step in management after the tachycardia recurs?

Was 18 mg Adenosine as First Dose Appropriate?

No, administering 18 mg adenosine as the initial dose was not correct—guidelines recommend starting with 6 mg, followed by 12 mg if needed, and then 18 mg as the third dose if the tachycardia persists. 1

Standard Adenosine Dosing Protocol

The ACC/AHA/HRS guidelines clearly establish a stepwise approach:

• First dose: 6 mg rapid IV bolus
• Second dose: 12 mg if tachycardia persists after 1-2 minutes
• Third dose: 18 mg if still no conversion 1

This graduated dosing strategy exists because there is a tenfold range in minimal effective dosage among patients 2, and starting at lower doses minimizes the risk of prolonged asystole and severe side effects while still achieving conversion in most patients. Research shows the mean effective dose for narrow-complex tachycardia is approximately 13 mg 3, meaning many patients convert with doses lower than 18 mg.

Why This Matters

Even though this patient has historically required 18 mg, each episode should be treated according to protocol because:

• The arrhythmia substrate may change over time
• Lower doses may become effective
• Starting high increases the risk of prolonged ventricular pauses (up to 6-7 seconds reported) 4, 2
• Adenosine can cause serious complications including cardiac arrest, sustained ventricular tachycardia, and myocardial infarction 5

---

What to Do Next After Recurrence

Since the patient is stable and adenosine caused only transient conversion, the next step is to administer IV calcium channel blockers (diltiazem or verapamil) or IV beta-blockers to achieve sustained rhythm control. 1

Immediate Management Algorithm

Step 1: Attempt Vagal Maneuvers Again

Even though adenosine was just given, repeat vagal maneuvers (modified Valsalva with legs elevated, carotid massage, or ice-water facial immersion) as the tachycardia may now be more susceptible to termination 1

Step 2: Administer AV Nodal Blocking Agents

Do NOT repeat adenosine at higher doses—there is no recommendation for doses above 18 mg, and the drug label does not support escalation beyond this 5

Instead, use long-acting AV nodal blockers:

Preferred options (Class I recommendation) 1:

• Diltiazem: 0.25 mg/kg IV over 2 minutes (typically 15-25 mg), can repeat at 0.35 mg/kg after 15 minutes if needed
• Verapamil: 5-10 mg IV over 2-3 minutes, can repeat 10 mg after 15-30 minutes
• IV beta-blockers (metoprolol 2.5-5 mg IV over 2 minutes, up to 3 doses; or esmolol loading dose 500 mcg/kg over 1 minute, then infusion)

These agents have 80-98% success rates for terminating AVNRT 1 and provide sustained effect, preventing the immediate recurrence seen with adenosine.

Step 3: If Pharmacologic Therapy Fails

Proceed to synchronized electrical cardioversion 1. This is a Class I recommendation for stable patients when pharmacologic therapy is ineffective. The patient should receive appropriate sedation/anesthesia before the procedure.

---

Critical Safety Considerations

Before Giving Calcium Channel Blockers or Beta-Blockers:

1. Confirm this is NOT pre-excited atrial fibrillation (WPW with AF)—the regular narrow-complex morphology and known AVNRT history make this unlikely, but if there is ANY uncertainty, these drugs are contraindicated as they can cause ventricular fibrillation 1

2. Assess for heart failure—avoid calcium channel blockers in patients with systolic dysfunction 1

3. Check blood pressure—ensure the patient remains hemodynamically stable

Why Adenosine Caused Transient Conversion Then Recurrence

This is a well-recognized limitation of adenosine occurring in approximately 35% of patients with junctional reentrant tachycardias 2. The extremely short half-life (<10 seconds) means that while it successfully blocks the AV node momentarily, the arrhythmia substrate remains intact and can reinitiate immediately. This is why an antiarrhythmic drug may be required to prevent acute reinitiation after successful adenosine conversion 1.

---

Definitive Management

This patient should be referred for catheter ablation given the recurrent, symptomatic nature of the AVNRT 6, 7. Slow pathway modification using radiofrequency energy has:

• >95% success rate
• <1% risk of complete AV block
• Curative intent, eliminating need for ongoing medications 8, 7

The 2019 ESC guidelines have elevated catheter ablation as the preferred long-term management strategy for symptomatic AVNRT 6, and it should be discussed with this patient as first-line definitive therapy rather than continuing to manage recurrent episodes pharmacologically.